News
Read our latest SpOTLight newsletter for a digest of OTL news:
-
SPOTLIGHT - Fall 2025
Cover Story: The Untold History of the First Commercial Router. Also: Startup Successes, Featured Technologies, and more!
October 14, 2025
Read additional news about OTL, our licensees, and Stanford technologies:
-
SPOTLIGHT - Fall 2025
Cover Story: The Untold History of the First Commercial Router. Also: Startup Successes, Featured Technologies, and more!
October 14, 2025
-
Inside the Invention of the Stanford Router That Inspired Cisco
Bill Yeager’s multiprotocol router, invented on campus in 1980, was the basis for Cisco’s first product.
October 08, 2025
-
July 09, 2025
-
Illuminating the Immune System with Silicon Photonics
From Stanford OTL's Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
Tiny But Bright: High-Performance Lasers Go Chip Scale
From Stanford OTL's Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
Secret Sauce: A New Hydrogel for Vaccines, Surgical Recovery, Wildfires, and More
From Stanford OTL's Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
Two Steps Forward: New Integrin-Binding Molecule is a ‘Guided Missile’
From Stanford OTL's Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
SPOTLIGHT June 2025 - Annual Report FY2024
This edition brings you our Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
A game-changing way to treat stroke
Profile of HIT Fund Awardee: Milli-Spinner
June 04, 2025
-
Hitting Its Stride
Teams Raise Capital, Find Playbook for Commercialization
June 01, 2025
-
May 30, 2025
-
Stanford HIT Fund Opens 2025 Call for Applications
Applications are due June 22, 2025
May 19, 2025
-
HIT Fund: Helping Stanford innovators commercialize their research
HIT Fund awardees share their perspectives
May 12, 2025
-
Stanford Licensee Abeona Therapeutics receives U.S. FDA Approval for ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure.
April 29, 2025
-
New tool lets scientists observe genome dynamics in real time
A technique to see DNA as it moves in living cells could offer novel fundamental insights into biology.
April 25, 2025
-
‘Engineering is fundamentally about solving problems’
Profile of HIT Fund Awardee: Eric Appel, Injectable Hydrogels
April 17, 2025
-
Stanford Licensee Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
Epic Bio is a biotechnology company focused on developing curative therapies.
April 03, 2025
-
HIT Fund Lab to Market Seminar Series: Open Source Considerations
Isaac Fine, Partner, KPPB, shares insights with the Stanford community
February 20, 2025
-
January 24, 2025
-
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
Vera Therapeutics has announced an exclusive license agreement with Stanford University.
January 13, 2025
